ARENA PHARMACEUTICALS INC (ARNA)
Institutional ownership reported to the SEC as of Q2 2026, across 29 quarters.
1
Reporting holders
$100
Reported value
0.0%
Held as options
+0
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| HUNTINGTON NATIONAL BANK | $100 | 1 | 0.00% | 15q | HELD |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q1 2026 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q4 2025 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q3 2025 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q2 2025 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q1 2025 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q4 2024 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q3 2024 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q2 2024 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q1 2024 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q4 2023 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q3 2023 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q2 2023 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q1 2023 | 1 | $100 | 1 | 0 | 0 | 0 | 0.0% |
| Q4 2022 | 1 | $100 | 1 | 1 | 0 | 0 | 0.0% |
| Q1 2022 | 1 | $1.0K | 2 | 1 | 0 | 0 | 0.0% |
| Q4 2021 | 320 | $5.3B | 53,287,063 | 111 | 71 | 87 | 5.7% |
| Q3 2021 | 239 | $3.4B | 56,259,633 | 33 | 91 | 63 | 2.7% |
| Q2 2021 | 239 | $3.9B | 56,758,264 | 35 | 79 | 72 | 1.2% |
| Q1 2021 | 237 | $3.9B | 56,054,617 | 19 | 77 | 88 | 1.2% |
| Q4 2020 | 259 | $4.3B | 54,461,737 | 31 | 80 | 97 | 1.6% |
| Q3 2020 | 257 | $4.1B | 52,966,453 | 36 | 78 | 90 | 3.2% |
| Q2 2020 | 246 | $3.5B | 54,445,251 | 60 | 81 | 71 | 1.9% |
| Q1 2020 | 217 | $2.0B | 46,167,813 | 32 | 75 | 66 | 0.8% |
| Q4 2019 | 227 | $2.0B | 43,224,358 | 22 | 72 | 71 | 2.4% |
| Q3 2019 | 228 | $2.0B | 43,904,383 | 38 | 80 | 58 | 1.4% |
| Q2 2019 | 217 | $2.6B | 43,637,135 | 56 | 66 | 43 | 2.4% |
| Q1 2019 | 189 | $1.9B | 42,534,559 | 29 | 57 | 52 | 1.7% |
| Q4 2018 | 176 | $1.6B | 40,641,396 | 5 | 6 | 3 | 1.7% |